Like other juries before it, an Arkansas panel found that the company's Janssen unit soft-pedaled the antipsychotic drug's risks.
The idea is to allow its former contract manufacturer to formulate the cancer drug, and then send it elsewhere for filling and packaging.
By jumping through some manufacturing hoops, Johnson & Johnson hopes to ease the shortage of its cancer drug Doxil by this fall.
Sherilyn McCoy is leaving J&J to become CEO of Avon, where she'll face investor unrest after the company rejected a takeover bid from fragrance maker Coty.
Sherilyn McCoy is taking a well-worn path out of her vice chairman's job: She's accepted another CEO post, shortly after losing out in the horse race for J&J's top slot.
FDA advisors have backed approval for Levaquin for a new use that the federal government had pushed for.
For all the bad press metal-on-metal hips generate these days over potential malfunctioning and other safety concerns, a new study offers a small piece of good news: The implants don't appear to boost cancer risks after their first 7 years of use.
Forest Laboratories has bought full rights to a blood-pressure drug co-marketed with Johnson & Johnson.
The bad news just keeps on coming in for manufactures of metal-on-metal hips. This morning, Johnson & Johnson ($JNJ) and Stryker ($SYK) are feeling the heat from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA).
Gorsky hasn't been made available to the media, but colleagues say he's a strong leader and a good communicator.